Description du projet
Un nouveau traitement médicamenteux pour l’alcoolisme
L’alcoolisme ou trouble de consommation d’alcool (AUD) est une préoccupation majeure dans l’UE et dans le monde. Le traitement implique généralement un processus de désintoxication difficile nécessitant un soutien physique et mental pour aider le patient à renoncer à l’alcool. Les thérapies médicamenteuses actuelles ne sont pas optimales et peuvent entraîner des effets secondaires graves. Le projet StopAddict, financé par l’UE, se prépare à inverser cette tendance. Le projet mettra sur le marché un nouveau médicament appelé KT-110. Développé par la société française Kinnov-Therapeutics, ce nouveau médicament de première classe permettra aux patients de contrôler leur consommation d’alcool. L’efficacité du KT-110, après 20 ans de recherche et de développement préclinique, est liée à son action sur une voie nouvellement découverte fortement impliquée dans la dépendance à l’alcool.
Objectif
Alcohol use disorders (AUD) is a disease characterised by uncontrolled alcohol consumption. 283 million persons worldwide suffer from alcohol mise use which cause more than 3 million dead and 132.6 million disability-adjusted life years. Alcoholism has also huge damaging effects on families, communities and the overall society. Current drug therapies against AUD are unsuccessful due to poor efficacy and strong side effects. That situation leads to low patient recovery and only 10% of AUD people seeking for treatment.
In this context, Kinnov-Therapeutics has developed a new revolutionary first-in-class drug allowing patients to control their alcohol consumption. KT-110 drug will highly impact the European burden of AUD by decreasing alcohol consumption on AUD patients by 70% leading to triple the number of AUD people seeking for treatments and save more than 5 million lives per year and several billion of social cost expenses. The efficacy of KT-110 is related to its action on a newly discovered pathway highly implicated in alcohol addiction. This major understanding of AUD addiction mechanism was granted the European college of neuropsychopharmacology Neuropsychopharmacology Award in 2009.
After 20 years of intensive research and pre-clinical development, KT-110 has been accepted by the french regulatory agency for its first-in man phase II clinical trial by the end of 2018. This will be the main achievement of SMEi2 project. Moreover, all necessary actions for successful commercialisation to pharma companies (licensing deals) as well as continuous and updated IP and FTO issues are planned to be implemented during the SMEi2.
Through StopAddict project KT-110 will become the next leader of AUD treatments by generating €117m of cumulative revenues between 2025-2027. Our project will also allow to create more than 400 direct and indirect European jobs.
Champ scientifique
Programme(s)
Régime de financement
SME - SME instrumentCoordinateur
45100 Orleans
France
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.